Biopharmaceutical company developing an investigational siRNA medicine targeting sFlt1 for preterm preeclampsia, with the goal of reducing excess protein production and improving outcomes for mothers and babies
Biopharmaceutical company developing an investigational siRNA medicine targeting sFlt1 for preterm preeclampsia, with the goal of reducing excess protein production and improving outcomes for mothers and babies.